Uptravi Generic Name & Formulations
Selexipag 200mcg, 400mcg, 600mcg, 800mcg, 1000mcg, 1200mcg, 1400mcg, 1600mcg; tabs.
Prostacyclin receptor agonist.
Tabs 200mcg—60, 140; 400mcg, 600mcg, 800mcg, 1000mcg, 1200mcg, 1400mcg, 1600mcg—60; Titration pack—1 (140 x 200mcg tabs) + (60 x 800mcg tabs); Single-dose vial (10mL)—1
Pulmonary arterial hypertension (PAH) (WHO Group 1) in patients with WHO functional Class II–III symptoms, to delay disease progression and reduce the risk of hospitalization for PAH.
Uptravi Dosage and Administration
Swallow whole; may take with food to improve tolerability. Initially 200mcg twice daily; increase by 200mcg increments twice daily at weekly intervals to highest tolerated dose up to 1600mcg twice daily; reduce to previous dose if not tolerated. Moderate hepatic impairment (Child-Pugh class B): initially 200mcg once daily; increase in 200mcg increments once daily at weekly intervals as tolerated. Concomitant moderate CYP2C8 inhibitors: reduce Uptravi dose to once daily.
Concomitant strong CYP2C8 inhibitors (eg, gemfibrozil).
Uptravi Boxed Warnings
Discontinue if pulmonary veno-occlusive disease confirmed. Severe hepatic impairment (Child-Pugh class C): avoid. Pregnancy. Nursing mothers: not recommended.
See Contraindications. Potentiated by moderate CYP2C8 inhibitors (eg, clopidogrel, deferasirox, teriflunomide); reduce dosing (see Adults). Antagonized by CYP2C8 and UGT 1A3 or 2B7 inducers (eg, rifampin); increase up to twice the dose.
Uptravi Adverse Reactions
Headache, diarrhea, nausea, jaw pain, vomiting, pain in extremity, myalgia, flushing, arthralgia, rash, anemia, decreased appetite.
Uptravi Clinical Trials
Uptravi Patient Counseling